Overweight (BMI > 25)NCT07196852
Redox Status and Exercise Training-induced Adaptations
A study testing N Acetyl L Cysteine in people with Overweight (BMI > 25) and Obesity, run by University of Thessaly at 1 site in Greece.
Trial summary
Excess fat accumulation is a key feature of overweight and obesity that is mainly driven by nutrient overload and insufficient physical activity. White adipose tissue displays lipid overload and hypertrophy accompanied by macrophages infiltration, hypoxia, inflammation and excess production of reactive oxygen species… Read more about this study
- Who is it for?
- Ages 30 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Overweight (BMI > 25), Obesity
- What is being tested?
- N Acetyl L Cysteine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteGreece
- Study dates
- 22 Sep 2025to 30 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- BMI 25-35 kg/m2
- Free of musculoskeletal injuries
- Free of chronic non-communicable diseases
- Do not receive any drug therapy
- Do not receive dietary supplements
- Normal menstrual cycle (for females)
- Non smokers
Who cannot join
- NAC intolerance
- Bleeding disorders
- Kidney disease
- Asthma
- Usage of blood thinners and/or angina medication
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Greece1 site, 1 recruiting
- Recruiting
Department of Physical Education and Sport Science, University of Thessaly
Trikala, Karies, 42100
Dimitrios Draganidis, PhD, +30 2431047078, ddraganidis@uth.gr
Ioannis G. Fatouros, PhD, +30 2431047047, ifatouros@uth.gr
About this study
Official title: Effects of N-acetylcysteine on Biological Responses to High-intensity Interval Training in Adults With Overweight/Obesity
Excess fat accumulation is a key feature of overweight and obesity that is mainly driven by nutrient overload and insufficient physical activity. White adipose tissue displays lipid overload and hypertrophy accompanied by macrophages infiltration, hypoxia, inflammation and excess production of reactive oxygen species (ROS). An inflammatory response and ROS production are also evident in other metabolism regulating tissues and organs such as skeletal muscle, liver, pancreas and hypothalamus, contributing to a chronic inflammatory state, redox status disturbances and metabolic complications. There is overwhelming evidence showing that adults with overweight/obesity exhibit lower glutathione (GSH) levels in blood erythrocytes, skeletal muscle cells and subcutaneous and visceral adipose tissue cells. GSH, a tripeptide consisting of the amino acids glutamate, cysteine and glycine, is the most abundant thiol-containing antioxidant in the human body and has been, recently, characterized as a novel therapeutic target for the treatment of numerous chronic diseases, due to its potent intracellular redox buffering capacity. Interestingly, lower GSH levels have been associated with diet-induced weight loss resistance, while enhancement of GSH levels through N-acetylcysteine (NAC) supplementation reduces markers of oxidative stress, inflammation, insulin resistance, hypertension, endothelia dysfunction and improves vitamin D metabolism. NAC is a thiol donor that elicits antioxidant effects by (i) directly scavenging ROS and (ii) providing reduced cysteine through deacetylation, which supports the biosynthesis of endogenous GSH via the activity of γ-glutamylcysteine synthase. The aim of this study is to investigate whether NAC supplementation can enhance the exercise training-induced improvements on physical fitness and metabolic health in adult men and women with overweight/obesity.
Read the detailed description
Forty adults with overweight/obesity (both males and females, aged 35-45 years) who will meet the inclusion criteria will be randomly assigned to a Placebo (Pla, n=20, will be supplemented with 2 placebo pills daily over a 12-week period) or a NAC (NAC, n=20 will be supplemented with 2 pills x 600 mg N-acetylcysteine daily over a 12-week period) group. Both groups will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period. At baseline, 6 weeks and 12 weeks participants will undergo assessment of their (i) anthropometrics (body weight, waist and hip circumferences) (ii) body composition (through total body DXA scan), (iii) fat liver content (via high-resolution ultrasound), (iv) cardiorespiratory fitness (determination of VO2max), (v) muscle strength (upper and lower body), (vi) habitual physical activity level (via accelerometry) and (vii) daily dietary intake (via dietary recalls). In addition, at the same time-points (Baseline, 6 weeks, 12 weeks), resting blood samples will be collected for the determination of (viii) blood redox status [reduced glutathione (GSH), oxidized glutathione (GSSH), GSH/GSSG, glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD) and catalase (CAT)], (ix) peripheral blood mononuclear cells antioxidant levels and markers of oxidative stress and inflammation (catalase, superoxide dismutase, glutathione peroxidase, glutathione reductase, malondialdehyde, TNF-α and Interleukin-6), (x) low-grade systemic inflammation [C-reactive protein (CRP) and Interleukin-6 (IL-6)], (xi) lipidemic profile (triglycerides, total cholesterol, HDL, LDL) and (xii) liver function (SGPT, SGOT, γ-GT, ALP, Fetuin-A), and (xiii) an oral glucose tolerance test (using 75g glucose loading) will be performed.
- Conditions
- Overweight (BMI > 25), Obesity
- Being tested
- N Acetyl L Cysteine, Placebo
- Keywords
- overweight, obesity, N-acetylcysteine, high-intensity interval training
- Medical subject headings
- Overweight, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
N Acetyl L CysteineDietary supplement
Participants will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period while receiving daily 1200 mg N-acetylcysteine (2 pills x 600 mg/day ).
PlaceboDietary supplement
Participants will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period while receiving daily 2 placebo pills/day.
| Study group | Role | What they receive |
|---|---|---|
| N-acetylcysteine | Experimental | Oral N-acetylcysteine supplementation for 12 weeks (2 x 600 mg capsules/day) Receives: Dietary Supplement: N Acetyl L Cysteine |
| Placebo | Placebo comparator | Oral placebo supplementation for 12 weeks (2 placebo capsules/day) Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in body weight (kg)
Measured: At baseline, 6 weeks and 12 weeks
Change in waist circumference
Measured: At baseline, 6 weeks and 12 weeks
Change in hip circumference
Measured: At baseline, 6 weeks and 12 weeks
Change in fat mass (kg)
Fat mass will be assessed through dual energy X-ray absorptiometry (DXA)
Measured: At baseline, 6 weeks and 12 weeks
Change in body fat percent (%)
Body fat percent will be assessed through dual energy X-ray absorptiometry (DXA)
Measured: At baseline, 6 weeks and 12 weeks
Change in fat free mass (kg)
Fat free mass will be assessed through dual energy X-ray absorptiometry (DXA)
Measured: At baseline, 6 weeks and 12 weeks
Change in lean body mass (kg)
Lean body mass will be assessed through dual energy X-ray absorptiometry (DXA)
Measured: At baseline, 6 weeks and 12 weeks
Change in liver fat infiltration
Liver fat infiltration will be assessed through ultrasound elastography
Measured: At baseline and 12 weeks
Change in cardiorespiratory fitness
Maximal oxygen consumption (VO2max) will be estimated during a single stage treadmill test (Ebbeling single stage test)
Measured: At baseline, 6 weeks and 12 weeks
Change in lower body muscle strength
Maximal concentric peak torque will be assessed on an isokinetic dynamometer
Measured: At baseline, 6 weeks and 12 weeks
Change in upper body muscle strength
Upper body muscle strength will be assessed through the abdominal strength test and the push-up test
Measured: At baseline, 6 weeks and 12 weeks
Change in reduced glutathione (GSH) concentration
GSH concentration will be determined in blood erythrocytes and peripheral blood mononuclear cells
Measured: At baseline, 6 weeks and 12 weeks
Change in oxidized glutathione (GSSG) concentration
GSSG concentration will be determined in blood erythrocytes and peripheral blood mononuclear cells
Measured: At baseline, 6 weeks and 12 weeks
Change in glutathione peroxidase (GPx) activity
GPx activity will be determined in blood erythrocytes and peripheral blood mononuclear cells
Measured: At baseline, 6 weeks and 12 weeks
Change in glutathione reductase (GR) activity
GR activity will be determined in blood erythrocytes and peripheral blood mononuclear cells
Measured: At baseline, 6 weeks and 12 weeks
Change in catalase activity
Catalase activity will be determined in blood erythrocytes and peripheral blood mononuclear cells
Measured: At baseline, 6 weeks and 12 weeks
Change in superoxide dismutase (SOD) activity
SOD activity will be determined in blood erythrocytes and peripheral blood mononuclear cells
Measured: At baseline, 6 weeks and 12 weeks
Change in malondialdehyde concentration
Malondialdehyde concentration will be determined in peripheral blood mononuclear cells
Measured: At baseline, 6 weeks and 12 weeks
Change in C-reactive protein (CRP) concentration
Measured: At baseline, 6 weeks and 12 weeks
Change in TNF-α concentration
TNF-α concentration will be determined in blood and peripheral blood mononuclear cells
Measured: At baseline, 6 weeks and 12 weeks
Change in interleukin-6 (IL-6) concentration
IL-6 concentration will be determined in blood and peripheral blood mononuclear cells
Measured: At baseline, 6 weeks and 12 weeks
Change in HDL cholesterol concentration
HDL cholesterol concentration will be determined in blood
Measured: At baseline, 6 weeks and 12 weeks
Change in LDL cholesterol concentration
LDL cholesterol concentration will be determined in blood
Measured: At baseline, 6 weeks and 12 weeks
Change in total cholesterol concentration
Total cholesterol concentration will be determined in blood
Measured: At baseline, 6 weeks and 12 weeks
Change in triglycerides concentration
Triglycerides concentration will be determined in blood
Measured: At baseline, 6 weeks and 12 weeks
Change in serum glutamic-oxaloacetic transaminase (SGOT/AST) concentration
SGOT concentration will be determined in blood
Measured: At baseline, 6 weeks and 12 weeks
Alanine Aminotransferase (SGPT/ALT) concentration
SGPT concentration will be determined in blood
Measured: At baseline, 6 weeks and 12 weeks
Change in Gamma-glutamyl transpeptidase (γ-GT) concentration
γ-GT concentration will be determined in blood
Measured: At baseline, 6 weeks and 12 weeks
Change in fetuin-A concentration
Fetuin-A concentration will be determined in blood
Measured: At baseline, 6 weeks and 12 weeks
Change in alkaline phosphatase (ALP) concentration
ALP concentration will be determined in blood
Measured: At baseline, 6 weeks and 12 weeks
Change in glucose concentration
Glucose concentration will be determined in blood
Measured: At baseline, 6 weeks and 12 weeks
Change in glycated hemoglobin (HbA1c) concentration
HbA1c concentration will be determined in blood
Measured: At baseline, 6 weeks and 12 weeks
Change in insulin concentration
Insulin concentration will be determined in blood
Measured: At baseline, 6 weeks and 12 weeks
Secondary outcomes (3)
Change in dietary intake
Dietary intake will be monitored through diet recalls
Measured: At baseline, 6 weeks and 12 weeks
Change in total number of steps
Total number of steps performed per day will be assessed by using accelerometers
Measured: At baseline, 6 weeks and 12 weeks
Change in time spent in moderate-to-vigorous physical activity
The time spent in moderate-to-vigorous physical activity per day will be assessed by using accelerometers
Measured: At baseline, 6 weeks and 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Sep 2025
- Study start22 Sep 2025
- Primary completion30 Jun 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Overweight (BMI > 25)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized clinical trial with repeated measures
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Thessaly
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dimitrios Draganidis, University of Thessaly
- Investigators
- Anastasia Rosvoglou, PhDc, Principal investigator, University of Thessaly, Department of Physical Education and Sport ScienceDimitrios Draganidis, PhD, Study director, University of Thessaly, Department of Physical Education and Sport Science
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07196852
- Sponsor's protocol ID
- UTH-2568_2.4.2025
- Status last verified
- Dec 2025
- First submitted
- 19 Sep 2025
- Last updated
- 16 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of N-acetylcysteine on Biological Responses to High-intensity Interval Training in Adults With Overweight/Obesity
- ClinicalTrials.gov ID
- NCT07196852
- Acronym / sponsor ID
- UTH-2568_2.4.2025
- Conditions
- Overweight (BMI > 25), Obesity
- Keywords
- overweight, obesity, N-acetylcysteine, high-intensity interval training
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University of ThessalyUniversity, hospital or other
- Study start
- 22 Sep 2025 (actual)
- Primary completion
- 30 Jun 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 29 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Excess fat accumulation is a key feature of overweight and obesity that is mainly driven by nutrient overload and insufficient physical activity. White adipose tissue displays lipid overload and hypertrophy accompanied by macrophages infiltration, hypoxia, inflammation and excess production of reactive oxygen species (ROS). An inflammatory response and ROS production are also evident in other metabolism regulating tissues and organs such as skeletal muscle, liver, pancreas and hypothalamus, contributing to a chronic inflammatory state, redox status disturbances and metabolic complications. There is overwhelming evidence showing that adults with overweight/obesity exhibit lower glutathione (GSH) levels in blood erythrocytes, skeletal muscle cells and subcutaneous and visceral adipose tissue cells. GSH, a tripeptide consisting of the amino acids glutamate, cysteine and glycine, is the most abundant thiol-containing antioxidant in the human body and has been, recently, characterized as a novel therapeutic target for the treatment of numerous chronic diseases, due to its potent intracellular redox buffering capacity. Interestingly, lower GSH levels have been associated with diet-induced weight loss resistance, while enhancement of GSH levels through N-acetylcysteine (NAC) supplementation reduces markers of oxidative stress, inflammation, insulin resistance, hypertension, endothelia dysfunction and improves vitamin D metabolism. NAC is a thiol donor that elicits antioxidant effects by (i) directly scavenging ROS and (ii) providing reduced cysteine through deacetylation, which supports the biosynthesis of endogenous GSH via the activity of γ-glutamylcysteine synthase. The aim of this study is to investigate whether NAC supplementation can enhance the exercise training-induced improvements on physical fitness and metabolic health in adult men and women with overweight/obesity.
Detailed description
Forty adults with overweight/obesity (both males and females, aged 35-45 years) who will meet the inclusion criteria will be randomly assigned to a Placebo (Pla, n=20, will be supplemented with 2 placebo pills daily over a 12-week period) or a NAC (NAC, n=20 will be supplemented with 2 pills x 600 mg N-acetylcysteine daily over a 12-week period) group. Both groups will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period. At baseline, 6 weeks and 12 weeks participants will undergo assessment of their (i) anthropometrics (body weight, waist and hip circumferences) (ii) body composition (through total body DXA scan), (iii) fat liver content (via high-resolution ultrasound), (iv) cardiorespiratory fitness (determination of VO2max), (v) muscle strength (upper and lower body), (vi) habitual physical activity level (via accelerometry) and (vii) daily dietary intake (via dietary recalls). In addition, at the same time-points (Baseline, 6 weeks, 12 weeks), resting blood samples will be collected for the determination of (viii) blood redox status [reduced glutathione (GSH), oxidized glutathione (GSSH), GSH/GSSG, glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD) and catalase (CAT)], (ix) peripheral blood mononuclear cells antioxidant levels and markers of oxidative stress and inflammation (catalase, superoxide dismutase, glutathione peroxidase, glutathione reductase, malondialdehyde, TNF-α and Interleukin-6), (x) low-grade systemic inflammation [C-reactive protein (CRP) and Interleukin-6 (IL-6)], (xi) lipidemic profile (triglycerides, total cholesterol, HDL, LDL) and (xii) liver function (SGPT, SGOT, γ-GT, ALP, Fetuin-A), and (xiii) an oral glucose tolerance test (using 75g glucose loading) will be performed.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized clinical trial with repeated measures
| Arm | Type | Receives |
|---|---|---|
| N-acetylcysteine | Experimental | Dietary Supplement: N Acetyl L CysteineOral N-acetylcysteine supplementation for 12 weeks (2 x 600 mg capsules/day) |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboOral placebo supplementation for 12 weeks (2 placebo capsules/day) |
Who may qualify
- Ages
- 30 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- BMI 25-35 kg/m2
- Free of musculoskeletal injuries
- Free of chronic non-communicable diseases
- Do not receive any drug therapy
- Do not receive dietary supplements
Key exclusion criteria (5 listed)
- NAC intolerance
- Bleeding disorders
- Kidney disease
- Asthma
- Usage of blood thinners and/or angina medication
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| N Acetyl L CysteineParticipants will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period while receiving daily 1200 mg N-acetylcysteine (2 pills x 600 mg/day ). | Dietary supplement | N-acetylcysteine |
| PlaceboParticipants will participate in 3 multicomponent high-intensity interval training (m-HIIT) sessions per week over a 12-week period while receiving daily 2 placebo pills/day. | Dietary supplement | Placebo |
Primary outcome
Change in body weight (kg)
Time frame: At baseline, 6 weeks and 12 weeks
Change in waist circumference
Time frame: At baseline, 6 weeks and 12 weeks
Change in hip circumference
Time frame: At baseline, 6 weeks and 12 weeks
Change in fat mass (kg)
Time frame: At baseline, 6 weeks and 12 weeks
Fat mass will be assessed through dual energy X-ray absorptiometry (DXA)
Change in body fat percent (%)
Time frame: At baseline, 6 weeks and 12 weeks
Body fat percent will be assessed through dual energy X-ray absorptiometry (DXA)
Change in fat free mass (kg)
Time frame: At baseline, 6 weeks and 12 weeks
Fat free mass will be assessed through dual energy X-ray absorptiometry (DXA)
Change in lean body mass (kg)
Time frame: At baseline, 6 weeks and 12 weeks
Lean body mass will be assessed through dual energy X-ray absorptiometry (DXA)
Change in liver fat infiltration
Time frame: At baseline and 12 weeks
Liver fat infiltration will be assessed through ultrasound elastography
Change in cardiorespiratory fitness
Time frame: At baseline, 6 weeks and 12 weeks
Maximal oxygen consumption (VO2max) will be estimated during a single stage treadmill test (Ebbeling single stage test)
Change in lower body muscle strength
Time frame: At baseline, 6 weeks and 12 weeks
Maximal concentric peak torque will be assessed on an isokinetic dynamometer
Change in upper body muscle strength
Time frame: At baseline, 6 weeks and 12 weeks
Upper body muscle strength will be assessed through the abdominal strength test and the push-up test
Change in reduced glutathione (GSH) concentration
Time frame: At baseline, 6 weeks and 12 weeks
GSH concentration will be determined in blood erythrocytes and peripheral blood mononuclear cells
Change in oxidized glutathione (GSSG) concentration
Time frame: At baseline, 6 weeks and 12 weeks
GSSG concentration will be determined in blood erythrocytes and peripheral blood mononuclear cells
Change in glutathione peroxidase (GPx) activity
Time frame: At baseline, 6 weeks and 12 weeks
GPx activity will be determined in blood erythrocytes and peripheral blood mononuclear cells
Change in glutathione reductase (GR) activity
Time frame: At baseline, 6 weeks and 12 weeks
GR activity will be determined in blood erythrocytes and peripheral blood mononuclear cells
Change in catalase activity
Time frame: At baseline, 6 weeks and 12 weeks
Catalase activity will be determined in blood erythrocytes and peripheral blood mononuclear cells
Change in superoxide dismutase (SOD) activity
Time frame: At baseline, 6 weeks and 12 weeks
SOD activity will be determined in blood erythrocytes and peripheral blood mononuclear cells
Change in malondialdehyde concentration
Time frame: At baseline, 6 weeks and 12 weeks
Malondialdehyde concentration will be determined in peripheral blood mononuclear cells
Change in C-reactive protein (CRP) concentration
Time frame: At baseline, 6 weeks and 12 weeks
Change in TNF-α concentration
Time frame: At baseline, 6 weeks and 12 weeks
TNF-α concentration will be determined in blood and peripheral blood mononuclear cells
Change in interleukin-6 (IL-6) concentration
Time frame: At baseline, 6 weeks and 12 weeks
IL-6 concentration will be determined in blood and peripheral blood mononuclear cells
Change in HDL cholesterol concentration
Time frame: At baseline, 6 weeks and 12 weeks
HDL cholesterol concentration will be determined in blood
Change in LDL cholesterol concentration
Time frame: At baseline, 6 weeks and 12 weeks
LDL cholesterol concentration will be determined in blood
Change in total cholesterol concentration
Time frame: At baseline, 6 weeks and 12 weeks
Total cholesterol concentration will be determined in blood
Change in triglycerides concentration
Time frame: At baseline, 6 weeks and 12 weeks
Triglycerides concentration will be determined in blood
Change in serum glutamic-oxaloacetic transaminase (SGOT/AST) concentration
Time frame: At baseline, 6 weeks and 12 weeks
SGOT concentration will be determined in blood
Alanine Aminotransferase (SGPT/ALT) concentration
Time frame: At baseline, 6 weeks and 12 weeks
SGPT concentration will be determined in blood
Change in Gamma-glutamyl transpeptidase (γ-GT) concentration
Time frame: At baseline, 6 weeks and 12 weeks
γ-GT concentration will be determined in blood
Change in fetuin-A concentration
Time frame: At baseline, 6 weeks and 12 weeks
Fetuin-A concentration will be determined in blood
Change in alkaline phosphatase (ALP) concentration
Time frame: At baseline, 6 weeks and 12 weeks
ALP concentration will be determined in blood
Change in glucose concentration
Time frame: At baseline, 6 weeks and 12 weeks
Glucose concentration will be determined in blood
Change in glycated hemoglobin (HbA1c) concentration
Time frame: At baseline, 6 weeks and 12 weeks
HbA1c concentration will be determined in blood
Change in insulin concentration
Time frame: At baseline, 6 weeks and 12 weeks
Insulin concentration will be determined in blood
3 secondary outcomes
Change in dietary intake
Time frame: At baseline, 6 weeks and 12 weeks
Change in total number of steps
Time frame: At baseline, 6 weeks and 12 weeks
Change in time spent in moderate-to-vigorous physical activity
Time frame: At baseline, 6 weeks and 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Dec 2025.
Related trials for Overweight (BMI > 25)
Active, not recruiting
Weight Loss and Endocrine Disrupting Chemicals (EDCs): Lifestyle Interventions to Lose Weight and Reduce EDC Exposure in Individuals With Overweight/Obesity
Obesity &Amp;Amp;Amp; Overweight, Environmental Exposure
Not yet recruiting
WB-EMS Combined With Nutritional Guidance for a High-Protein Diet on Body Composition, Muscle Function, Psychological and Functional Outcomes in Older Adults With Excess Adiposity
Overweight (BMI > 25), Obesity & Overweight
Recruiting
Probiotic Impact on Cognitive Performance, and Metabolic Outcomes in Overweight Young Adults With Impaired Glucose Regulation
Impaired Glucose Regulation, Impaired Glucose Tolerance (Prediabetes)
Active, not recruitingEarly Phase 1
L. Acidophilus (Strain TW01) on Gut Health, Body Composition, and Inflammation
Overweight (BMI > 25), Obese, Otherwise Healthy Volunteers
RecruitingPhase 2
Investigation of the Efficacy of a Probiotic Mixture in Moderate Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Mechanistic Trial
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Fatty Liver Disease, Nonalcoholic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Anastasia Rosvoglou, PhDc principal investigator
University of Thessaly, Department of Physical Education and Sport Science
Dimitrios Draganidis, PhD study director
University of Thessaly, Department of Physical Education and Sport Science
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing N Acetyl L Cysteine in people with Overweight (BMI > 25) and Obesity, run by University of Thessaly at 1 site in Greece.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Dimitrios Draganidis, PhD (+30 2431047078, ddraganidis@uth.gr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in body weight (kg) (time frame: At baseline, 6 weeks and 12 weeks). The study lists 33 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Dec 2025.